@article{23ee6c71a67b4432a79b6aeafddc3c98,
title = "Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities",
abstract = "Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybridization for del(5q31).",
keywords = "Aged, Aged, 80 and over, Antineoplastic Agents, Base Sequence, Chromosome Aberrations, Chromosomes, Human, Pair 5, Female, Gene Expression Regulation, Leukemic, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Oncogene Protein p21(ras), Thalidomide, Treatment Outcome, Tumor Markers, Biological, Tumor Suppressor Protein p53, WT1 Proteins",
author = "Lars M{\"o}llg{\aa}rd and Leonie Saft and Treppendahl, {Marianne Bach} and Ingunn Dybedal and N{\o}rgaard, {Jan Maxwell} and Jan Astermark and Elisabeth Ejerblad and Hege Garelius and Dufva, {Inge H{\o}gh} and Monika Jansson and Martin J{\"a}dersten and Lars Kjeldsen and Olle Linder and Nilsson, {Lars Ola} and Hanne Vestergaard and Anna Porwit and Kirsten Gr{\o}nb{\ae}k and Eva Hellstr{\"o}m-Lindberg and Lindberg, {Eva Hellstr{\"o}m}",
year = "2011",
doi = "10.3324/haematol.2010.039669",
language = "English",
volume = "96",
pages = "963--71",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",
}